Controlled Substance Scheduling Amendments

2026 General Session Introduced by Logan Monson and 1 co-sponsor

SB 83 automatically aligns Utah’s scheduling with federal changes for pharmaceutical compositions of Schedule I substances starting May 6, 2026.

Governor Signed

#controlledsubstances #healthcare #healthandhumanservices #occupationalandprofessionallicensing #pharmaceuticals

Overview

SB 83, from the 2026 Utah General Session, amends the state's controlled substance scheduling framework. The bill’s primary aim is to streamline scheduling alignment with federal actions by enabling automatic rescheduling of a pharmaceutical composition when the corresponding Schedule I substance is rescheduled at the federal level. The bill takes effect May 6, 2026 and does not include new revenue or explicit new expenditures.

Main purpose and intent

Synchronize Utah’s scheduling with federal changes without requiring separate state action.

Specifically, if the federal government schedules a pharmaceutical composition of a Schedule I controlled substance, Utah will treat that pharmaceutical composition as scheduled in the same way and in the same schedule, pursuant to state law.

Key provisions and changes

Section 1, 58-37-4 (Schedules of controlled substances):

Reiterates Utah’s five schedules (I–V) and lists the substances covered.
Adds a mechanism for automatic rescheduling of a “pharmaceutical composition” of a Schedule I substance if the federal government reschedules that composition (in any form not already Schedule I at the federal level, but the composition is scheduled under federal law). In such a case, the Utah scheduling would mirror the federal schedule for that pharmaceutical composition.
The text clarifies how the rescheduling would align with federal scheduling under 21 U.S.C. 812 and 21 C.F.R. Part 1308.

Section 2, Effective Date:

The act becomes effective on May 6, 2026.

Who or what would be affected

Entities handling controlled substances in Utah (pharmacies, hospitals, clinics, researchers, and suppliers) would be subject to the automatic alignment when federal scheduling changes occur for a pharmaceutical composition of a Schedule I substance.

State law enforcement, regulatory agencies, and judiciary would follow the updated Utah Schedule without requiring separate legislative action for each federal change.

Procedural and timeline aspects

The bill passed through the Utah Legislature with committee recommendations (Health and Human Services in both Senate and House).

It received House amendments and was enrolled and signed in late February to March 2026, followed by executive action in March 2026.

Effective date is May 6, 2026, providing a short lead time to implement the automatic rescheduling mechanism.

Fiscal impact

The fiscal note states no direct state revenue or expenditure changes are expected.

The bill could modestly increase regulatory burden due to automatic cross-referencing with federal changes, but no new programs or funding are created.

In summary, SB 83 automates Utah’s alignment with federal rescheduling for pharmaceutical compositions of Schedule I substances, reducing the need for separate state action and ensuring consistency between federal and Utah schedules starting May 6, 2026.